MedOPP107 4 marzo, 2019 / 0 TwittearCompartirCompartir0 CompartirMulticenter, open-label, phase II trial to evaluate the efficacy and safety of naI-IRI for progressing brain metastases in patients with HER2 negative breast cancer.TwittearCompartirCompartir0 Compartir